Evolus (LTS:0K16) Current Accrued Expense : $21.7 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Evolus Current Accrued Expense?

Evolus's Current Accrued Expense for the quarter that ended in Sep. 2024 was $21.7 Mil.

Evolus's quarterly Current Accrued Expense increased from Mar. 2024 ($16.3 Mil) to Jun. 2024 ($21.0 Mil) and increased from Jun. 2024 ($21.0 Mil) to Sep. 2024 ($21.7 Mil).

Evolus's annual Current Accrued Expense declined from Dec. 2021 ($37.1 Mil) to Dec. 2022 ($20.8 Mil) but then increased from Dec. 2022 ($20.8 Mil) to Dec. 2023 ($22.8 Mil).

Evolus Current Accrued Expense Historical Data

The historical data trend for Evolus's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Current Accrued Expense Chart

Evolus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

12.25

69.44

37.06

20.78

22.78

Evolus Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Accrued Expense	Get a 7-Day Free Trial															17.93	22.78	16.35	21.00	21.72

Evolus Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Evolus Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Evolus's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (LTS:0K16) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

EOLS:USA EVL:Germany

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines